Skip to main content
Premium Trial:

Request an Annual Quote

Human Genome Sciences And Transgene Sign Gene Therapy Drug Deal

Premium

ROCKVILLE, Md.--Human Genome Sciences here and French biotechnology company Transgene announced in early March a 10-year agreement to accelerate the development of novel gene therapy drugs. HGS will combine its genomics database with Transgene's broad technology platform of gene delivery systems, the companies said.

Transgene will have rights to exclusively license and sublicense up to 10 genes and to develop, manufacture, and commercialize any resulting gene therapy products worldwide.

HGS will take a 10 percent interest in Trangene's equity, and Transgene will pay an initial licensing fee and research funding in an amount equal to the proceeds to Trangene from the HGS purchase. Transgene will pay royalties on future sales and partnering revenues to HGS.

Filed under

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.